Peptic Ulcer Drugs MarketSize and Trends

Global Peptic Ulcer Drugs market is estimated to be valued at US$ 34.34 Billion in 2023 and is expected to exhibit a CAGR of 4.1% during the forecast period (2023-2030). Increase in product launches by key market players is expected to drive the market growth over the forecast period. Moreover, an increase in government and non-government organizations' initiatives to improve access to affordable vision care and an increase in awareness among people regarding eye-related disease are expected to drive the market growth during the forecast period.

Figure 1. Global Peptic Ulcer Drugs Market Share (%), by Product Type, 2023

Global Peptic Ulcer Drugs Market- Driver

Increasing prevalence of peptic ulcers

Increasing in the prevalence of peptic ulcer is a major factor boosting growth of the global peptic ulcer drugs market over the forecast period. For instance, data published in April 2021, stated that in the U.S, peptic ulcer disease affects approximately 4.6 million people every year.

Increase in the research and development activities

Increase in the research and development activities by the key players in the market is expected to drive the growth of the market over the forecast period. For instance, on January 4, 2023, Tanta University, based in Egypt, initiated a clinical study titled ‘Diosmin as Adjuvant Therapy in Treatment of Non-bleeding Peptic Ulcer.’ The study is expected to get completed by June 2025.

Figure 2. Global Peptic Ulcer Drugs Market Share (%), by Region, 2023

Market- Trends

Global Peptic Ulcer Drugs Market Segmentation:

The global peptic ulcer drugs market report is segmented into product type, disease indication and distribution channel.

Based on Product Type, the market is segmented into steroids, proton pump inhibitors, potassium-competitive acid blocker (p-cab), antacids, h2- antagonist, antibiotics and ulcer protective. Out of which, the Proton Pump Inhibitors segment is expected to dominate the golabl peptic ulcer drugs market during the forecast period and this is attributed to an increase in the product launches by key market players. For instance, in March 2021, Xiromed LLC, a U.S.-based generic division of Insud Pharmaceuticals, launched Omeprazole Delayed-Release Capsules, 20mg, generic for Prilose.

Based on Disease Indication, the market is segmented into gastitis, gastric ulcer, duodenal ulcer and gastroesophageal reflux disease (GERD). Out of which, the , duodenal ulcer segment is expected to dominate the global peptic ulcer drugs market during the forecast period and this is attributed to an increase in the global prevalence of gastric ulcer. For instance, data published in April 2021, on Medscape, stated that every year approximately 10% of the U.S. population suffer from duodenal ulcer.

Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Out of which, the hospital pharmacies segment is expected to dominate the market over the forecast period and this is attributed to an increase in the number of hospital pharmacies. For instance, on September 19, 2022, Apollo Pharmacy, a part of the Apollo Hospitals Group, announced the opening of its 5,000th store in India.

Global Peptic Ulcer Drugs Market Cross Sectional Analysis:

In the product type segment, proton pump inhibitors segment held a dominant position in the Asia Pacific region due to the increasing in adoption of inorganic growth strategies agreements by key market players. For instance, in March 2021, Daiichi Sankyo Co., Ltd., a pharmaceutical company, made an agreement for transferring the marketing and distribution rights for the proton pump inhibitor Nexium capsules 10 mg and 20 mg and Nexium granules for suspension 10 mg and 20 mg (esomeprazole magnesium) to AstraZeneca in Japan.

In disease indication segment, Gastric Ulcer segment held a dominant position in the North America region due to the increasing in research and development activities by key market players. For instance, on June 9, 2020, Spital Limmattal Schlieren, a general and teaching hospital based in Switzerland, initiated a clinical study titled ‘Functional Changes in the Stomach and Esophagus After One Anastomosis Gastric Bypass- OAGB- BiFlux Trial.’ The study is estimated to get completed on May 28, 2028.

Key Market Trends

Increasing product launches, prevalence of peptic ulcers and increase in the research and development activities by key players are anticipated market drivers for the Global Peptic Ulcer Drugs market in near-term future.